Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03384563 · ClinicalTrials.gov registry record · Phase 4

Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane

A Phase 4 study of Pediatric Anesthesia, sponsored by Baylor College of Medicine.

Recruiting
Registry status
Phase 4
Development phase
180
Enrollment target
1
Study location

NCT03384563 is a Phase 4 study of Pediatric Anesthesia that is actively recruiting participants, run by Baylor College of Medicine. The registered enrollment target is 180 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03384563, a Phase 4 study of Pediatric Anesthesia, is actively recruiting participants, sponsored by Baylor College of Medicine.

RECRUITING
Registry status
Phase 4
Development phase
180 participants
Enrollment target
1
Study location

Study Summary

The purpose of this protocol is to determine the effect of two clinically applicable Dexmedetomidine dosages (0.5mcg/kg and 1mcg/kg) on the minimum alveolar concentration (MAC) of Sevoflurane in children between the age ranges of: 1-6 months; 6-12 months of age and 12 months-36 months years of age.

Conditions Studied

Interventions

  • DRUG Dexmedetomidine

Study Locations (1)

Texas

  • Texas Children's Hospital - Houston

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2018-02-18
Est. Completion 2025-12-31
Phase Phase 4

Sponsor

Baylor College of Medicine

616 total trials

What the Registry Record Tells You About NCT03384563

The ClinicalTrials.gov registry entry for NCT03384563 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pediatric Anesthesia appearing as the primary indexed condition, and to 1 intervention - of which Dexmedetomidine is the first listed.

NCT03384563 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT03384563 about?

NCT03384563 is a clinical study titled "Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane". The purpose of this protocol is to determine the effect of two clinically applicable Dexmedetomidine dosages (0.5mcg/kg and 1mcg/kg) on the minimum alveolar concentration (MAC) of Sevoflurane in children between the age ranges of: 1-6 months; 6-12 months of age and 12 months-36 months years of age.

What is the current status of trial NCT03384563?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 180 participants. The study started on 2018-02-18. Estimated completion is 2025-12-31.

What conditions does trial NCT03384563 study?

This clinical trial studies the following conditions: Pediatric Anesthesia.

What interventions are being tested in trial NCT03384563?

The interventions under investigation include: Dexmedetomidine (DRUG).

Who is sponsoring clinical trial NCT03384563?

This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03384563 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.